Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche issues new tender offer for Genentech
The offer replaces the previous proposal made by Roche in July 2008 to acquire all of the publicly held shares of Genentech at a price of $89 per
The offer replaces the previous proposal made by Roche in July 2008 to acquire all of the publicly held shares of Genentech at a price of $89 per
Revenues for the second quarter decreased $404,012 or 16.8% vs. the prior year’s comparable quarter; of this, $179,365 was a reduction in contract manufacturing revenue primarily due to
In the primary analysis, there was no statistically significant difference between maribavir and placebo in reducing the rate of cytomegalovirus (CMV) disease. In addition, the study failed to
The study successfully demonstrated the tolerability of the two concentrations tested for continuous application to the skin for a period of one week. Additionally, there was no systemic
Xoma, a biopharmaceutical company, and Takeda Pharmaceutical Company have expanded their existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of R&D technologies
The reduction in costs is targeted at Akela’s development programs, as well as its service business, PharmaForm. Akela has initiated the Phase III clinical trials in its lead
The new contract is expected to generate $5 million in sales for Medline, while CHS is in line to realize a 20% supply cost savings through formulary standardization,
ATryn is said to be the first ever transgenically produced therapeutic protein and the first recombinant antithrombin approved in the US. It is now also the first recombinant
If approved, Arzerra (ofatumumab) would be indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) who have previously failed, or are inappropriate for, standard therapies. Ofatumumab
In his most recent endeavor, he served as chief executive officer (CEO) of Living Cell Technologies. He was earlier president and CEO of Aurogen, a privately held biotech